Longboard pharmaceuticals receives breakthrough therapy designation for bexicaserin (lp352)

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the fda has granted breakthrough therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with developmental and epileptic encephalopathies (dees) for patients two years of age or older. “we are thrilled to receive breakthroug.
LBPH Ratings Summary
LBPH Quant Ranking